Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Global University Venturing

C4 Therapeutics seals $170m round

The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.


Jun 17, 2020

Goel moves into UToronto’s Covid-19 response

Vivek Goel will move into a coronavirus response-oriented advisory role having been University of Toronto vice-president for research, innovation and strategic initiatives since 2015.

Jun 17, 2020

Wandelbots wins $30m

Wandelbots, which came out of Technical University of Dresden research, secured the funding as it publicly launched its robotics training software tool.

Jun 17, 2020

Daily deal net: June 17, 2020

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jun 17, 2020

4DMT materialises $75m series C round

4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

Jun 17, 2020
Jun 17, 2020

Tech giants reinforce country’s strength

Innovative region: Singapore

Jun 17, 2020

Which way forward for education?

With campuses shuttered in the pandemic, society needs to find solutions quickly to continue education and avoid a lost generation of skilled workers.

Jun 17, 2020

Health sector stays strong

Sector analysis: Health & life sciences

Jun 17, 2020

Covid-19 likely to prompt strategy change

Global Corporate Venturing ran a short survey of corporate venture capital investors on the impact of the Covid-19 pandemic in April.

Jun 17, 2020

GCV musters CVCs at its first digital forum

Global Corporate Venturing hosted its first virtual conference, GCV Digital Forum, on June 3 and 4 with a special networking space and ideas challenge.

Jun 17, 2020

CureVac gets a $339m kick from KfW

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Jun 16, 2020
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here